These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 6127944)

  • 1. Prolongation of the human cardiac monophasic action potential by sotalol.
    Echt DS; Berte LE; Clusin WT; Samuelsson RG; Harrison DC; Mason JW
    Am J Cardiol; 1982 Nov; 50(5):1082-6. PubMed ID: 6127944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sotalol exhibits reverse use-dependent action on monophasic action potentials in normal but not in infarcted canine ventricular myocardium.
    Schmitt C; Beyer T; Karch M; Montero M; Hilbel T; Brachmann J; Kübler W
    J Cardiovasc Pharmacol; 1992 Apr; 19(4):487-92. PubMed ID: 1380589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of sotalol, aprindine and the combination aprindine-sotalol on monophasic action potential duration.
    Stroobandt R; Brachmann J; Kesteloot H; Kübler W; Senges J
    Eur Heart J; 1986 Jan; 7(1):47-53. PubMed ID: 3956522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Electrophysiological effects of MS-551, a new class III agent: comparison with dl-sotalol in dogs.
    Sen L; Cui G; Sakaguchi Y; Singh BN
    J Pharmacol Exp Ther; 1998 May; 285(2):687-94. PubMed ID: 9580614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the class III antiarrhythmic drug dofetilide on ventricular monophasic action potential duration and QT interval dispersion in stable angina pectoris.
    Sedgwick ML; Rasmussen HS; Cobbe SM
    Am J Cardiol; 1992 Dec; 70(18):1432-7. PubMed ID: 1442614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reverse use-dependent effects of sotalol demonstrated by recording monophasic action potentials of the right ventricle.
    Schmitt C; Brachmann J; Karch M; Waldecker B; Navarrete L; Montero M; Beyer T; Kübler W
    Am J Cardiol; 1991 Nov; 68(11):1183-7. PubMed ID: 1951078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reverse use dependence of human ventricular repolarization by chronic oral sotalol in monophasic action potential recordings.
    Shimizu W; Kurita T; Suyama K; Aihara N; Kamakura S; Shimomura K
    Am J Cardiol; 1996 May; 77(11):1004-8. PubMed ID: 8644624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of chronic treatment by amiodarone on transmural heterogeneity of canine ventricular repolarization in vivo: interactions with acute sotalol.
    Merot J; Charpentier F; Poirier JM; Coutris G; Weissenburger J
    Cardiovasc Res; 1999 Nov; 44(2):303-14. PubMed ID: 10690307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome.
    Milberg P; Tegelkamp R; Osada N; Schimpf R; Wolpert C; Breithardt G; Borggrefe M; Eckardt L
    J Cardiovasc Electrophysiol; 2007 Jun; 18(6):658-64. PubMed ID: 17521304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Electrophysiologic effects of the levo- and dextrorotatory isomers of sotalol in isolated cardiac muscle and their in vivo pharmacokinetics.
    Kato R; Ikeda N; Yabek SM; Kannan R; Singh BN
    J Am Coll Cardiol; 1986 Jan; 7(1):116-25. PubMed ID: 3941198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of electropharmacological effects of bepridil and sotalol in halothane-anesthetized dogs.
    Ishizaka T; Takahara A; Iwasaki H; Mitsumori Y; Kise H; Nakamura Y; Sugiyama A
    Circ J; 2008 Jun; 72(6):1003-11. PubMed ID: 18503230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sympathetic activation, ventricular repolarization and Ikr blockade: implications for the antifibrillatory efficacy of potassium channel blocking agents.
    Vanoli E; Priori SG; Nakagawa H; Hirao K; Napolitano C; Diehl L; Lazzara R; Schwartz PJ
    J Am Coll Cardiol; 1995 Jun; 25(7):1609-14. PubMed ID: 7759713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the electropharmacological effects of verapamil and propranolol in the halothane-anesthetized in vivo canine model under monophasic action potential monitoring.
    Shiina H; Sugiyama A; Takahara A; Satoh Y; Hashimoto K
    Jpn Circ J; 2000 Oct; 64(10):777-82. PubMed ID: 11059619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positive and negative inotropic effects of DL-sotalol and D-sotalol in failing and nonfailing human myocardium under physiological experimental conditions.
    Holubarsch C; Schneider R; Pieske B; Ruf T; Hasenfuss G; Fraedrich G; Posival H; Just H
    Circulation; 1995 Nov; 92(10):2904-10. PubMed ID: 7586258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of nipradilol (K-351) on the electrophysiological properties of canine cardiac tissues: comparison with propranolol and sotalol.
    Nakaya H; Kimura S; Nakao Y; Kanno M
    Eur J Pharmacol; 1984 Sep; 104(3-4):335-44. PubMed ID: 6149947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologic basis of the antiarrhythmic and hemodynamic effects of sotalol.
    Antonaccio MJ; Gomoll A
    Am J Cardiol; 1993 Aug; 72(4):27A-37A. PubMed ID: 8346723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged ventricular refractoriness and action potential duration after beta-adrenoreceptor blockade in the dog heart in situ.
    Amlie JP; Refsum H; Landmark KH
    J Cardiovasc Pharmacol; 1982; 4(1):157-62. PubMed ID: 6176793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of sotalol and acute ventricular dilatation on action potential duration and dispersion of repolarization after defibrillation shocks.
    Kirchhof P; Milberg P; Eckardt L; Breithardt G; Haverkamp W
    J Cardiovasc Pharmacol; 2003 Apr; 41(4):640-8. PubMed ID: 12658067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular electrophysiological effects of D- and DL-sotalol in guinea-pig sinoatrial node, atrium and ventricle and human atrium: differential tissue sensitivity.
    Campbell TJ
    Br J Pharmacol; 1987 Mar; 90(3):593-9. PubMed ID: 3567463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolongation of monophasic action potential duration and the refractory period in the human heart by tedisamil, a new potassium-blocking agent.
    Bargheer K; Bode F; Klein HU; Trappe HJ; Franz MR; Lichtlen PR
    Eur Heart J; 1994 Oct; 15(10):1409-14. PubMed ID: 7821321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.